The QQQM exchange-traded fund has been highlighted as the ETF of the Week, drawing attention to its performance and investment potential.

An article discusses the strategic advantages and considerations for investors holding the QQQM ETF within a Roth IRA account.

This series of articles compares various Exchange Traded Funds (ETFs) in the biotechnology and growth sectors. The comparisons aim to help investors determine which ETFs, such as SPDR S&P Pharmaceuticals vs. First Trust NYSE Arca Biotech, or QQQM vs. VGT, offer better value in terms of fees and growth potential for their portfolios.

QQQM's 0.15% fee is highlighted as a significant advantage over QQQ for long-term growth investors, leading to better returns.

This article compares QQQ and QQQM, both tracking the Nasdaq-100 Index, to identify which is the clearer winner for long-term investors.

An analysis argues that the QQQM ETF is a superior investment choice compared to the QQQ ETF, citing a specific powerful reason.

SpaceX is set to join the Nasdaq-100 index on July 7, a move that will impact investors in funds like QQQ and QQQM. The inclusion of the aerospace company is expected to add to the volatility of the index.

An analysis suggests that the QQQM ETF carries more risk than its reputation as a low-cost, 'set-it-and-forget-it' investment implies, prompting investors to re-evaluate its safety.